Monica Forbes Biography and Net Worth

CFO of Sesen Bio

Monica Forbes serves as Sesen Bio’s chief financial officer. Ms. Forbes brings more than 20 years of financial leadership experience to Sesen Bio, including prior experience leading the finance and administrative functions of late and commercial-stage public and private life science companies. Ms. Forbes most recently served as the chief financial officer of Nalpropion Pharmaceuticals where she led the integration of a newly acquired asset and supporting commercial team. Prior to that, Ms. Forbes served as the acting chief financial officer of Orexigen Therapeutics where she oversaw all finance and administrative operations for the publicly traded company and played a key role in the successful sale of the company. Prior to being appointed acting chief financial officer at Orexigen, Ms. Forbes held various leadership roles with expertise in financial planning and analysis, budgeting, forecasting and business development across companies such as AstraZeneca, Invitrogen, Ericsson and Qualcomm. Ms. Forbes holds a Bachelor of Science in Business Administration from San Diego State University.

What is Monica Forbes' net worth?: The estimated net worth of Monica Forbes is at least $0.00 as of March 2nd, 2023. Ms. Forbes owns 16,306 shares of Sesen Bio stock worth more than $0 as of April 27th. This net worth approximation does not reflect any other assets that Ms. Forbes may own. Learn More about Monica Forbes' net worth.
How do I contact Monica Forbes?: The corporate mailing address for Ms. Forbes and other Sesen Bio executives is 245 FIRST STREET SUITE 1800, CAMBRIDGE MA, 02142. Sesen Bio can also be reached via phone at (617) 444-8550 and via email at [email protected]. Learn More on Monica Forbes' contact information.
Has Monica Forbes been buying or selling shares of Sesen Bio?: Monica Forbes has not been actively trading shares of Sesen Bio during the past quarter. Most recently, Monica Forbes sold 17,292 shares of the business's stock in a transaction on Thursday, March 2nd. The shares were sold at an average price of $11.80, for a transaction totalling $204,045.60. Following the completion of the sale, the chief financial officer now directly owns 16,306 shares of the company's stock, valued at $192,410.80. Learn More on Monica Forbes' trading history.
Who are Sesen Bio's active insiders?: Sesen Bio's insider roster includes Thomas Cannell (CEO), Monica Forbes (CFO), Glen Macdonald (CTO), and Mark Sullivan (General Counsel). Learn More on Sesen Bio's active insiders.

Monica Forbes Insider Trading History at Sesen Bio

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
3/2/2023	Sell	17,292	$11.80	$204,045.60	16,306
2/21/2023	Sell	3,093	$11.80	$36,497.40	24,019

Monica Forbes Buying and Selling Activity at Sesen Bio

Sesen Bio Company Overview

Sesen Bio, Inc. engages in designing, engineering, and developing targeted protein therapeutics. It offers Vicineum and Proxinium, which target tumor cell surface antigens that allow for rapid internalization into the targeted cancer cell and also have limited expression on normal cells. The company was founded by Reza Dana, K. Christopher Garcia, Gregory L. Verdine, Casey T. Weaver and K. Dane Wittrup on February 25, 2008 and is headquartered in Cambridge, MA.

Today's Range

Now: N/A

50 Day Range

MA: $10.50

$0.63

$12.99

2 Week Range

Now: N/A

Volume

93,330 shs

Average Volume

1,067,298 shs

Market Capitalization

$2.56 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.83

Forget AI, Imperium Is Expected to Grow 320,00% in 3 Years

From Banyan Hill Publishing | Ad

If you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)

Watch my video for all of the details